DIVISLAB

Divi's Laboratories Limited · NSE · INE361B01024 · F&O · lot 100 · 272 sessions on record

₹9,249.00▼ −42.50 · −0.5%from ₹9,291.50 the session before · 1 Oct 2026 close · NSE end of day

Open: ₹9,277.00
High: ₹9,318.00
Low: ₹9,078.00
Day's range: ₹2402.6% of the previous close
VWAP: ₹9,187.18close +0.67% from it
Volume, shares: 5.7 L1.14× the 20-session average
Turnover, ₹ crore: 520
Trades: 57,00010 shares per trade
Previous close: ₹9,291.50−42.50 to the close
Price band, next session: ₹8,324.10 – ₹10,173.9010% either side of the close · dynamic, widened in 5% steps when hit

Day range71% of the way up

₹9,078.00₹9,318.00

52-week range88% of the way up

₹5,647.50 2 Apr₹9,740.00 24 Sept

−5.0% from the high · +64% from the low

The desk read · 1 Octexpiry 27 Oct · 26 days

short build-up

futures read

price −0.5% · OI +1.0%

+17.50

futures premium, ₹

+0.2% to spot ₹9,249.00

0.59

puts per call, by OI

by volume 0.87

9,500

max pain

+2.7% from the close

▲ +1.0%

futures OI on the day

+430 lots · 44,000 open

Short build-up into a 26-day expiry: futures OI +1.0% on a −0.5% day, the most call OI sits at 10,000, the most put OI at 8,500, max pain 9,500.

Futures and options

1 Oct close · lot 100 · NSE end of day

DIVISLAB futures closed at ₹9,266.50, +0.2% to spot, with 89% of open interest in the 27 Oct contract, and the 9,200 straddle prices a move of about ±5.3% by expiry.

Futures by expiryall 3 contracts NSE lists on the stock · basis against the spot close ₹9,249.00

Futures by expiry, basis against the spot close ₹9,249.00
Expiry	Close ₹	Basis ₹ · %	Annualised %	OI lots · on the day	Share of OI %	Contracts traded
27 Oct26 days	₹9,266.50	+17.50+0.2%	+2.7%	39,000▲ +0.9% · +340 lots	89	3,800
23 Nov53 days	₹9,306.50	+57.50+0.6%	+4.3%	4,700▲ +1.2% · +57 lots	11	330
29 Dec89 days	₹9,351.00	+102.00+1.1%	+4.5%	47▲ +213.3% · +32 lots	0.11	48

11% of futures OI sits beyond the 27 Oct contract · 42 of 53 listed contracts traded · 35,000 option contracts changed hands

Options27 Oct expiry · 26 days

The 9,200 straddle closed at ₹488.05 (call 277.65 + put 210.40), pricing a move of about ±5.3% by the 27 Oct expiry. In the last 253 windows of 19 sessions, DIVISLAB moved more than that 124 times.

Call OI, lots: 15,00015 L shares
Put OI, lots: 9,0009.0 L shares
Puts per call, by OI: 0.59by volume 0.87
Max pain: 9,500+2.7% from the close
Contracts traded: 42 of 53listed for this expiry

Open interest by strike, lotstop three strikes each side

Calls

Strike

Puts

3,800

10,000

1,600

9,600

3,000

9,500

1,000

9,000

800

8,500

1,100

Open interest added on the day, lotsthree largest additions each side

Calls

Strike

Puts

+590

10,400

+130

9,300

+170

9,100

8,600

+210

8,300

+700

8,000

+92

Close ₹ · Nifty 50 rebased to the first close · futures open interest by the day's build-up126 sessions to 1 Oct · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it

272 sessions on file · from 28 Aug

DIVISLAB close
Nifty 50, rebased
long build-up · price up, OI up
short build-up · price down, OI up
short covering · price up, OI down
long unwinding · price down, OI down

Session read · latest close: 1 Oct 2026
Close ₹ · day %: ₹9,249.00▼ −0.5% on the previous close
Against Nifty 50: Nifty −0.9%+0.4 pp difference on the day
Futures OI, lots: 44,000+430 lots · +1.0% on the day
The day's build-up: short build-upprice −0.5% · OI +1.0%
Against the averages: below 20 · above 5020-session ₹9,383.60 (−1.4%) · 50-session ₹8,807.67 (+5.0%)
Volume: 1.14×the previous 20 sessions · 5.7 L shares
Extremes on the day: none

The market after the news

close against the last close before each bulletin · Nifty 50 over the same sessions

After the last 6 bulletins, DIVISLAB closed higher five sessions later in 1 of 6.

Close after each bulletin on the day, one session later and five sessions later, with Nifty 50 and futures open interest
Bulletin	Day of the news	1 session later	5 sessions later	Futures OI on the day
26 MayDivi's Laboratories reports annual results, analysts adjust forecasts	▼ −0.1%Nifty −0.5% · +0.4 pp	▲ +0.6%Nifty −0.5% · +1.1 pp	▼ −2.7%Nifty −2.6% · −0.1 pp	▲ +2.6%short build-up
24 MayDivi’s Labs Q4 net profit rises 13% to ₹751 cr	▼ −1.9%Nifty +1.3% · −3.2 pp	▼ −1.9%Nifty +0.8% · −2.8 pp	▼ −5.1%Nifty −1.0% · −4.2 pp	▲ +2.9%short build-up
23 MayDivi's Laboratories Q4 net profit rises 13% to ₹751 crore	▼ −1.9%Nifty +1.3% · −3.2 pp	▼ −1.9%Nifty +0.8% · −2.8 pp	▼ −5.1%Nifty −1.0% · −4.2 pp	▲ +2.9%short build-up
19 MayGland Pharma boosts drug stocks as weak rupee enhances margins	▲ +1.1%Nifty −0.1% · +1.3 pp	▲ +0.8%Nifty 0.0% · +0.8 pp	▼ −1.2%Nifty +1.1% · −2.3 pp	▼ −0.2%short covering
4 MayPharma Q4 outlook mixed with steady hospitals and generics pressure	▲ +1.8%Nifty +0.5% · +1.3 pp	▲ +2.3%Nifty +0.1% · +2.1 pp	▲ +3.3%Nifty −0.8% · +4.0 pp	▼ −0.6%short covering
11 FebDivi's Labs Q3 net profit dips to ₹583 crore, income rises 12%	▼ −3.2%Nifty −0.6% · −2.6 pp	▼ −3.4%Nifty −1.9% · −1.6 pp	▼ −1.4%Nifty −1.9% · +0.5 pp	▲ +3.8%short build-up

6 of 6 bulletins

Quarterly results

consolidated · latest filed 1 Aug, 01:05 pm IST · NSE filings

Revenue ₹3,080 cr, +28% on a year earlier; profit ₹902 cr, +66% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidated₹ crore as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, Nifty 50 over the same session

Quarterly results of DIVISLAB on the consolidated basis with the market's move on the first session after each filing
Quarter	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹	Market on the day
Jun 2026filed 1 Aug	₹3,080 cr	▲ +28%	₹902 cr	▲ +66%	33.95	▲ +6.6%Nifty +1.6% · +5.0 pp
Mar 2026filed 23 May · audited	₹10,560 cr	▲ +310%	₹2,568 cr	▲ +290%	96.75	▼ −1.9%Nifty +1.3% · −3.2 pp
Dec 2025filed 11 Feb	₹2,604 cr	▲ +12%	₹583 cr	▼ −1.0%	21.98	▲ +3.4%Nifty +0.1% · +3.4 pp
Sept 2025filed 7 Nov	₹2,715 cr	▲ +16%	₹689 cr	▲ +35%	25.97	▲ +0.5%Nifty +0.3% · +0.2 pp
Jun 2025filed 6 Aug	₹2,410 cr	▲ +14%	₹545 cr	▲ +27%	20.49	▼ −4.3%Nifty −0.3% · −4.0 pp
Mar 2025filed 17 May · audited	₹2,585 cr	▲ +12%	₹662 cr	▲ +23%	24.93	▲ +4.8%Nifty −0.3% · +5.1 pp
Dec 2024filed 3 Feb	₹2,319 cr	▲ +25%	₹589 cr	▲ +65%	22.20	▲ +3.6%Nifty +1.6% · +2.0 pp
Sept 2024filed 9 Nov	₹2,338 cr	▲ +22%	₹510 cr	▲ +47%	19.20	▼ −0.8%Nifty 0.0% · −0.8 pp

By financial yearApril to March · each year the sum of its four quarters as filed, consolidated · EPS summed across the quarters · only complete years

Financial-year results of DIVISLAB on the consolidated basis, summed from the quarters filed
Year	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹
FY26to Mar 2026	₹18,289 cr	▲ +95%	₹4,385 cr	▲ +100%	165.19
FY25to Mar 2025	₹9,360 cr	▲ +19%	₹2,191 cr	▲ +37%	82.53
FY24to Mar 2024	₹7,845 cr	—	₹1,600 cr	—	60.27

Fundamentals

consolidated · filings to Jun 2026 · close ₹9,249.00 on 1 Oct

DIVISLAB trades at 52 times trailing earnings against 38 for its industry, 15 times book value, revenue +96% over twelve months, a 0.65% dividend yield, market cap ₹2,50,000 cr.

Valuationarithmetic on filings and the close · each cell names what it rests on · — where an input is missing

Market cap: ₹2,50,000 cron 1 Oct · free float ₹1,20,000 cr
Price to earnings: 52consolidated · four quarters to Jun 2026 · industry 38
Trailing EPS: ₹178.65diluted · consolidated · four quarters to Jun 2026
Price to book: 15consolidated · balance sheet to Mar 2026
Book value a share: ₹631.37consolidated · balance sheet to Mar 2026 · over NSE's share count
Debt to equity: 0.00borrowings over equity · consolidated · balance sheet to Mar 2026
Return on equity: 30%trailing profit over average equity · consolidated
Dividend yield: 0.65%₹60.00 a share in 365 days
Face value: ₹2a share
Shares outstanding: 27 cron 1 Oct

Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated

Revenue, trailing 12 months: ₹18,959 crfour quarters to Jun 2026
Revenue growth, 12 months: ▲ +96%against the twelve months before
Revenue 2-year CAGR: ▲ +52%trailing twelve months against the twelve months 2 years earlier · consolidated
Profit, trailing 12 months: ₹4,742 crfour quarters to Jun 2026
Profit growth, 12 months: ▲ +110%against the twelve months before
Profit 2-year CAGR: ▲ +68%trailing twelve months against the twelve months 2 years earlier · consolidated

PeersBSE sub-group Pharmaceuticals · F&O stocks with filings on record · industry P/E 38, market caps over trailing profit of 13 stocks

Stocks in the BSE sub-group Pharmaceuticals with market cap, price to earnings and price to book
Stock	Market cap ₹	P/E	P/B	Close ₹
SUNPHARMASun Pharmaceutical Industries Limited	4,30,000 cron 1 Oct	36consolidated	5.2	₹1,801.00
DIVISLABDivi's Laboratories Limited	2,50,000 cron 1 Oct	52consolidated	15	₹9,249.00
TORNTPHARMTorrent Pharmaceuticals Limited	1,80,000 cron 1 Oct	76consolidated	10	₹4,767.30
ZYDUSLIFEZydus Lifesciences Limited	1,10,000 cron 1 Oct	26consolidated	3.9	₹1,145.70
CIPLACipla Limited	1,10,000 cron 1 Oct	32consolidated	3.1	₹1,344.00
LAURUSLABSLaurus Labs Limited	1,10,000 cron 1 Oct	85consolidated	20	₹1,984.00
MANKINDMankind Pharma Limited	1,00,000 cron 1 Oct	51consolidated	6.3	₹2,535.00
DRREDDYDr. Reddy's Laboratories Limited	1,00,000 cron 1 Oct	31consolidated	2.6	₹1,206.20
AUROPHARMAAurobindo Pharma Limited	96,000 cron 1 Oct	26consolidated	2.5	₹1,676.80
LUPINLupin Limited	93,000 cron 1 Oct	17consolidated	4.1	₹2,031.20
GLENMARKGlenmark Pharmaceuticals Limited	66,000 cron 1 Oct	37consolidated	6.3	₹2,331.00
ALKEMAlkem Laboratories Limited	62,000 cron 1 Oct	29consolidated	4.3	₹5,220.00
BIOCONBiocon Limited	60,000 cron 1 Oct	110consolidated	1.6	₹370.70
ABBOTINDIAAbbott India Limited	57,000 cron 1 Oct	—	—	₹26,840.00
IPCALABIPCA Laboratories Limited	49,000 cron 1 Oct	—	5.2	₹1,943.20
GLANDGland Pharma Limited	47,000 cron 1 Oct	—	4.6	₹2,874.40
GLAXOGlaxoSmithKline Pharmaceuticals Limited	47,000 cron 1 Oct	—	21	₹2,771.10
AJANTPHARMAjanta Pharma Limited	45,000 cron 1 Oct	—	9.9	₹3,581.00
EMCUREEmcure Pharmaceuticals Limited	37,000 cron 1 Oct	—	7.4	₹1,944.60
WOCKPHARMAWockhardt Limited	34,000 cron 1 Oct	—	6.4	₹2,083.90
SAILIFESai Life Sciences Limited	33,000 cron 1 Oct	—	13	₹1,541.20
NEULANDLABNeuland Laboratories Limited	28,000 cron 1 Oct	—	15	₹21,505.00
RUBICONRubicon Research Limited	27,000 cron 1 Oct	—	21	₹1,630.90
PPLPHARMAPiramal Pharma Limited	26,000 cron 1 Oct	—	3.2	₹197.95
ACUTAASAcutaas Chemicals Limited	26,000 cron 1 Oct	—	15	₹3,196.50
SHILPAMEDShilpa Medicare Limited	21,000 cron 1 Oct	—	8.0	₹1,064.10
GRANULESGranules India Limited	20,000 cron 1 Oct	—	4.0	₹821.75
CAPLIPOINTCaplin Point Laboratories Limited	20,000 cron 1 Oct	—	5.5	₹2,631.90
PFIZERPfizer Limited	18,000 cron 1 Oct	—	4.2	₹3,858.90
ONESOURCEOnesource Specialty Pharma Limited	17,000 cron 1 Oct	—	3.0	₹1,508.00
COHANCECohance Lifesciences Limited	17,000 cron 1 Oct	—	4.3	₹451.30
ALIVUSAlivus Life Sciences Limited	17,000 cron 1 Oct	—	5.1	₹1,374.20
ERISEris Lifesciences Limited	16,000 cron 1 Oct	—	4.2	₹1,189.80
NATCOPHARMNatco Pharma Limited	16,000 cron 1 Oct	—	1.8	₹821.30
APLLTDAlembic Pharmaceuticals Limited	16,000 cron 1 Oct	—	2.8	₹815.25
JUBLPHARMAJubilant Pharmova Limited	16,000 cron 1 Oct	—	2.2	₹999.30
ASTRAZENAstraZeneca Pharma India Limited	15,000 cron 1 Oct	—	17	₹6,031.00
MARKSANSMarksans Pharma Limited	15,000 cron 1 Oct	—	4.8	₹325.60
CONCORDBIOConcord Biotech Limited	14,000 cron 1 Oct	—	7.1	₹1,374.10
AKUMSAkums Drugs and Pharmaceuticals Limited	13,000 cron 1 Oct	—	3.8	₹813.10
CORONACORONA Remedies Limited	12,000 cron 1 Oct	—	17	₹2,029.40
BLUEJETBlue Jet Healthcare Limited	10,000 cron 1 Oct	—	7.5	₹541.80
VIYASHViyash Scientific Limited	10,000 cron 1 Oct	—	3.3	₹231.75
STARStrides Pharma Science Limited	10,000 cron 1 Oct	—	3.2	₹1,084.80
PGHLProcter & Gamble Health Limited	8,900 cron 1 Oct	—	17	₹5,360.00
AARTIPHARMAarti Pharmalabs Limited	8,800 cron 1 Oct	—	4.1	₹968.50
SANOFICONRSanofi Consumer Healthcare India Limited	8,700 cron 1 Oct	—	25	₹3,787.20
SYMBIOTECSymbiotec Pharmalab Limited	7,700 cron 1 Oct	—	—	₹1,198.00
SUPRIYASupriya Lifescience Limited	7,500 cron 1 Oct	—	6.3	₹931.00
MOREPENLABMorepen Laboratories Limited	7,300 cron 1 Oct	—	5.9	₹133.70
SANOFISanofi India Limited	7,000 cron 1 Oct	—	8.5	₹3,037.40
INNOVACAPInnova Captab Limited	6,700 cron 1 Oct	—	6.1	₹1,168.00
SPARCSun Pharma Advanced Research Company Limited	6,300 cron 1 Oct	—	4.7	₹194.15
SENORESSenores Pharmaceuticals Limited	6,200 cron 1 Oct	—	6.4	₹1,349.60
IOLCPIOL Chemicals and Pharmaceuticals Limited	6,100 cron 1 Oct	—	3.4	₹209.40
ORCHPHARMAOrchid Pharma Limited	5,900 cron 1 Oct	—	4.6	₹990.00
FDCFDC Limited	5,500 cron 1 Oct	—	2.2	₹335.90
GUJTHEMGujarat Themis Biosyn Limited	5,000 cron 1 Oct	—	—	₹381.80
NOVARTINDNovartis India Limited	4,900 cron 1 Oct	—	—	₹1,965.00
RPGLIFERPG Life Sciences Limited	4,800 cron 1 Oct	—	8.0	₹2,930.70
SMSPHARMASMS Pharmaceuticals Limited	4,400 cron 1 Oct	—	5.6	₹471.30
GUFICBIOGufic Biosciences Limited	4,200 cron 1 Oct	—	6.3	₹418.40
AARTIDRUGSAarti Drugs Limited	3,800 cron 1 Oct	—	2.5	₹421.00
UNICHEMLABUnichem Laboratories Limited	3,800 cron 1 Oct	—	1.4	₹535.05
KPLKwality Pharmaceuticals Limited	3,700 cron 1 Oct	—	—	₹3,564.40
SOLARASolara Active Pharma Sciences Limited	3,400 cron 1 Oct	—	2.7	₹714.85
INDSWFTLABInd-Swift Laboratories Limited	3,400 cron 1 Oct	—	2.5	₹395.15
SHUKRAPHARShukra Pharmaceuticals Limited	2,700 cron 1 Oct	—	—	₹61.80
HIKALHikal Limited	2,700 cron 1 Oct	—	2.2	₹218.15
VENUSREMVenus Remedies Limited	2,400 cron 1 Oct	—	3.6	₹1,796.70
DCALDishman Carbogen Amcis Limited	2,400 cron 1 Oct	—	0.35	₹150.35
INDOCOIndoco Remedies Limited	2,300 cron 1 Oct	—	2.5	₹251.75
SAIPARENTSai Parenterals Limited	2,300 cron 1 Oct	—	4.7	₹523.65
SYNCOMFSyncom Formulations (India) Limited	2,300 cron 1 Oct	—	5.4	₹23.95
FREDUNFredun Pharmaceuticals Limited	2,200 cron 1 Oct	—	—	₹1,355.20
WINDLASWindlas Biotech Limited	2,200 cron 1 Oct	—	—	₹1,082.40
PANACEABIOPanacea Biotec Limited	2,200 cron 1 Oct	—	2.6	₹359.05
HESTERBIOHester Biosciences Limited	1,800 cron 1 Oct	—	4.9	₹2,126.80
NGLFINENGL Fine-Chem Limited	1,800 cron 1 Oct	—	5.5	₹2,924.00
AHCLAnlon Healthcare Limited	1,700 cron 1 Oct	—	6.8	₹32.85
FERMENTAFermenta Biotech Limited	1,600 cron 1 Oct	—	—	₹553.25
JAGSNPHARMJagsonpal Pharmaceuticals Limited	1,500 cron 1 Oct	—	5.5	₹231.75
AMRUTANJANAmrutanjan Health Care Limited	1,500 cron 1 Oct	—	4.0	₹513.20
KOPRANKopran Limited	1,400 cron 1 Oct	—	2.6	₹282.05
BPLPHARMABharat Parenterals Limited	1,200 cron 1 Oct	—	—	₹1,720.40
LINCOLNLincoln Pharmaceuticals Limited	1,200 cron 1 Oct	—	1.5	₹582.05
BAJAJHCAREBajaj Healthcare Limited	1,100 cron 1 Oct	—	2.0	₹322.95
SIGACHISigachi Industries Limited	1,100 cron 1 Oct	—	2.0	₹28.35
THEMISMEDThemis Medicare Limited	1,000 cron 1 Oct	—	2.6	₹113.20
SGRLShree Ganesh Remedies Limited	890 cron 1 Oct	—	—	₹694.25
ANUHPHRAnuh Pharma Limited	860 cron 1 Oct	—	2.4	₹85.85
ZIMLABZim Laboratories Limited	740 cron 1 Oct	—	2.5	₹137.00
WANBURYWanbury Limited	690 cron 1 Oct	—	4.8	₹198.00
ALBERTDAVDAlbert David Limited	490 cron 1 Oct	—	1.3	₹856.70
MEDICAMEQMedicamen Biotech Limited	470 cron 17 Sept	—	1.7	₹346.30
HALEOSLABSHALEOS LABS LIMITED	450 cron 1 Oct	—	2.0	₹1,490.00
JENBURPHJenburkt Pharmaceuticals Limited	400 cron 1 Oct	—	—	₹915.25
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	290 cron 1 Oct	—	2.0	₹103.85
NECLIFENectar Lifesciences Limited	200 cron 1 Oct	—	0.34	₹10.25
MEDICOMedico Remedies Limited	180 cron 1 Oct	—	2.4	₹21.85
BALPHARMABal Pharma Limited	170 cron 1 Oct	—	2.0	₹105.75
BROOKSBrooks Laboratories Limited	160 cron 1 Oct	—	1.3	₹54.80
KREBSBIOKrebs Biochemicals and Industries Limited	150 cron 1 Oct	—	—	₹68.05
PARNAXLABParnax Lab Limited	130 cron 1 Oct	—	—	₹113.15
ALPAAlpa Laboratories Limited	120 cron 1 Oct	—	0.67	₹59.25
MAKERSLMakers Laboratories Limited	110 cron 1 Oct	—	—	₹183.50
SUNLOCSunil Healthcare Limited	72 cron 1 Oct	—	—	₹70.10
VINEETLABVineet Laboratories Limited	69 cron 1 Oct	—	1.5	₹35.90
BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited	48 cron 1 Oct	—	2.2	₹29.30
MANGALAMMangalam Drugs And Organics Limited	46 cron 1 Oct	—	0.45	₹29.15
MEDICAPQMedi Caps Limited	31 cron 17 Sept	—	—	₹24.80
ORTINGLOBEORTIN GLOBAL LIMITED	12 cron 1 Oct	—	9.5	₹14.50
AMANTAAmanta Healthcare Limited	—	—	—	—
AMBALALSAAmbalal Sarabhai Enterprises Limited	—	—	—	—
BAFNAPHBafna Pharmaceuticals Limited	—	—	—	—
BLISSGVSBliss GVS Pharma Limited	—	—	—	—
KILITCHKilitch Drugs (India) Limited	—	—	—	—
LASALasa Supergenerics Limited	—	—	—	—
LYKALABSLyka Labs Limited	—	—	—	—
NATCAPSUQNatural Capsules Limited	—	—	—	—
VALIANTLABValiant Laboratories Limited	—	—	—	—
VIVIMEDLABVivimed Labs Limited	—	—	—	—

Shareholding

quarter to 30 Jun · none pledged · NSE filings

Promoters hold 51.9%, foreign portfolio investors 20.2%, mutual funds 13.9% and insurance companies 4.5%, as filed for the quarter to 30 Jun.

51.9%20.2%13.9%

By category, last 5 quarterspercent of shares · beneath each figure, the change in percentage points against the previous quarter on file

Shareholding of DIVISLAB by category over the last 5 quarters with the change against the previous quarter
Category	30 Jun	31 Mar	31 Dec	30 Sept	30 Jun
Promoters	51.880.00 pp	51.880.00 pp	51.88▼ −0.01 pp	51.890.00 pp	51.89
Foreign portfolio investors	20.19▼ −0.10 pp	20.29▲ +0.21 pp	20.08▲ +0.69 pp	19.39▼ −0.35 pp	19.74
Mutual funds	13.87▲ +0.45 pp	13.42▼ −0.31 pp	13.73▼ −0.26 pp	13.99▲ +0.68 pp	13.31
Insurance companies	4.45▼ −0.29 pp	4.74▼ −0.18 pp	4.92▼ −0.19 pp	5.11▲ +0.01 pp	5.10
Banks and financial institutions	1.060.00 pp	1.06▲ +0.44 pp	0.62▼ −0.05 pp	0.67▲ +0.03 pp	0.64
Individual investors	6.85▼ −0.07 pp	6.92▼ −0.13 pp	7.05▼ −0.20 pp	7.25▼ −0.29 pp	7.54
Bodies corporate	1.190.00 pp	1.19▼ −0.01 pp	1.200.00 pp	1.20▼ −0.06 pp	1.26
Others	0.51▲ +0.01 pp	0.50▼ −0.02 pp	0.52▲ +0.01 pp	0.51▼ −0.01 pp	0.52

Corporate actions

NSE and BSE records

Nothing upcoming on record; the last was a dividend of ₹30.00 a share, ex-date 24 Jul 2026.

Actionsex-dates · upcoming first, then the last eight · dividends in rupees a share, bonus and split as ratios

Corporate actions of DIVISLAB, upcoming first, then the most recent
Ex-date	Action	Amount or ratio	Record date	Source
recent
24 Jul 2026	dividend	₹30.00	24 Jul 2026	BSE
25 Jul 2025	dividend	₹30.00	25 Jul 2025	BSE
2 Aug 2024	dividend	₹30.00	2 Aug 2024	BSE

Calendaras notified to the exchange

Next results: —no board meeting notified yet
Dividends in 365 days: ₹60.00a share · ex-dates inside the year
Last dividend: ₹30.00ex-date 24 Jul 2026

Price history

272 sessions on record · to 1 Oct · NSE end of day

DIVISLAB is +0.3% over 20 sessions against Nifty's −6.2%, 5.0% below its 52-week high, realised volatility 22% annualised.

Returns against Nifty 50longest window first · Nifty 50 over the same sessions

Returns of the stock and Nifty 50 over six windows, longest first
Window	From ₹	DIVISLAB %	Nifty 50 %	Difference pp
250 sessionssince 26 Sept	₹5,689.59	▲ +63%	▼ −9.1%	+72
120 sessionssince 9 Apr	₹5,952.50	▲ +55%	▼ −5.7%	+61
60 sessionssince 8 Jul	₹6,755.04	▲ +37%	▼ −6.1%	+43
20 sessionssince 2 Sept	₹9,220.42	▲ +0.31%	▼ −6.2%	+6.6
5 sessionssince 24 Sept	₹9,602.37	▼ −3.7%	▼ −2.8%	−0.90
1 sessionsince 30 Sept	₹9,291.74	▼ −0.46%	▼ −0.88%	+0.42

Averages of the closeclose against each average

5-session average: ₹9,428.20close −1.9% from it
20-session average: ₹9,383.60close −1.4% from it
50-session average: ₹8,807.67close +5.0% from it
200-session average: ₹7,037.65close +31% from it

Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average

Average true range, 14: ₹2002.1% of the close
Average day's range, 20: ₹1902.1% of the close
Volume against 20 sessions: 1.14×5.7 L vs 5.1 L average

Volatility and co-movement with Nifty 50annualised from daily log returns · counts share one denominator per cell

Realised volatility, 20: 22%≈ ±1.4% a session · moved more than that on 6 of 20
Realised volatility, 60: 28%≈ ±1.7% a session · moved more than that on 16 of 60
Realised volatility, 250: 24%≈ ±1.5% a session · moved more than that on 66 of 250
Beta to Nifty, 60: 1.08moved with Nifty on 38 of 60 sessions
Beta to Nifty, 250: 0.58moved with Nifty on 158 of 250 sessions

Up and down sessionscloses above and below the previous close

Last 20 sessions: 8 up · 12 downof 20
Last 60 sessions: 37 up · 23 downof 60
Last 250 sessions: 134 up · 114 downof 248
Best session, 250: ▲ +6.6%3 Aug
Worst session, 250: ▼ −3.4%13 Mar

Divi's Laboratories Limited is in 18 NSE indices

all 18 indices

6 bulletins on DIVISLAB

latest 26 May 2026

Beats in the coverage

Pharma4

Often mentioned with

May 2026

26 May Divi's Laboratories reports annual results, analysts adjust forecastsDivi's Laboratories reported revenues of ₹106b and earnings per share of ₹96.75, aligning with estimates. Analysts forecast revenues of ₹123.2b for 2027, reflecting a 17% increase, indicating positive sentiment for the company.Medium 24 May Divi’s Labs Q4 net profit rises 13% to ₹751 crDivi’s Laboratories reported a 13% rise in Q4 net profit to ₹751 crore, driven by total income of ₹2,986 crore. The company declared a ₹30 dividend, reflecting strong financial performance.Medium 23 May Divi's Laboratories Q4 net profit rises 13% to ₹751 croreDivi's Laboratories reported Q4 net profit of ₹751 crore, up 13% YoY, with revenue rising 10% to ₹2,831 crore. The company announced a final dividend of ₹30 per share, subject to AGM approval.Medium 19 May Gland Pharma boosts drug stocks as weak rupee enhances marginsGland Pharma's shares surged 15% as the rupee fell to a record low of 96.34, boosting margins and export revenues. Other pharma stocks also rallied, with gains of 9-16% in recent weeks, benefiting from increased global demand for generics.High 4 May Pharma Q4 outlook mixed with steady hospitals and generics pressurePharmaceuticals sector outlook for Q4 is mixed, with hospitals showing steady growth while generics face challenges from Revlimid sales decline. Lupin and Divi's are expected to perform well, while Sun Pharma benefits from strong domestic and international momentum.Medium

February 2026

11 Feb Divi's Labs Q3 net profit dips to ₹583 crore, income rises 12%Divi's Laboratories reported Q3FY26 net profit of ₹583 crore, down from ₹589 crore last year, while total income rose 12.1% to ₹2,692 crore. The company incurred a ₹74 crore loss due to new labor codes, affecting overall profitability.Medium

About Divi's Laboratories Limited

exchange masters as of 18 Sept 2026 · classification by BSE

Company: Divi's Laboratories Limited
Exchange: NSE · BSE 532488, group A
Listed on NSE: 12 Mar 2003
Classification: Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Index: BSE 100
Face value: ₹2 a share
ISIN: INE361B01024
Sessions on record: 272
Price source: NSE UDiFF bhavcopy · end of day · delayed
Filings: NSE and BSE public disclosures · results, shareholding and corporate actions as filed
Computed: 1 Oct, 09:04 pm IST
Bulletins: 6 · written by the desk · not a recommendation

OI Charts is not a SEBI-registered investment adviser or research analyst. Prices, open interest, filings and the desk read are exchange data and arithmetic on it, not a basis for any investment decision.